China Stockpiles Antivirals, Scraps Quarantine To Further Reopen Borders
Three months' supply to be stockpiled, cover 15-20% population
Incoming visitors won't be required to be centrally quarantined in designated facilities starting 8 January while the national health authority also calls to stockpile three months supply of antivirals to tackle acute shortages across the nation.
You may also be interested in...
The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.